ArticleAnnals of the rheumatic diseases2021

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.

Nicola Potere et al.PubMed ↗Publisher ↗

No numbers read from the abstract.